Skip to main content

Breadcrumb

  1. Home

Actigraphy Improvement With Voxelotor (ActIVe) Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Actigraphy Improvement With Voxelotor (ActIVe) Study

TTVR Early Feasibility Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about TTVR Early Feasibility Study

Cancer and Blood Pressure Management, CARISMA Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Cancer and Blood Pressure Management, CARISMA Study

TRISCEND II Pivotal Trial

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about TRISCEND II Pivotal Trial

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Cas

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Cas

ACTIV-3: Therapeutics for Inpatients With COVID-19

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about ACTIV-3: Therapeutics for Inpatients With COVID-19

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 204
  • Page 205
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • Page 212
  • …
  • Next page Next
  • Last page Last
Subscribe to